Pyxis Oncology, Inc. PYXS

2.86 (0.06) (2.05%) as of 25 Sep
Market cap
$250.2M
P/E
0.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
0.00 0.00 — — — — — —
P/S ratio
0.00 0.00 — — — — — —
P/FCF ratio
0.00 0.00 — — — — — —
P/Operating CF
(6.85) (4.73) — — — — — —
P/B ratio
1.34 0.76 — — — — — —
Price to Tangible BV
1.40 0.77 — — — — — —
EV/Sales
0.00 0.00 — — — — — —
EV/EBITDA
0.00 0.40 — — — — — —
EV/Operating CF
(0.05) 0.65 — — — — — —
EV/FCF
(0.05) 0.64 — — — — — —
Quick Ratio
3.23 7.26 4.69 5.71 14.76 2.19 26.86 —
Current Ratio
3.41 7.49 4.84 5.90 14.90 2.20 26.88 —
Net Debt/EBITDA
0.82 1.39 1.42 1.47 4.00 0.65 6.83 —
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.08% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Asset Turnover
0.11 0.10 0.00 0.00 0.00 0.00 0.00 —
Operating CF/Net income
0.80 0.75 0.96 0.74 0.47 0.79 0.81 —
Capex/Depreciation
(0.01) 0.08 2.35 (9.03) (0.83) (3.16) — —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
(91.43%) (62.75%) (51.51%) (57.19%) (61.85%) 138.54% 29.94% —
ROA
(64.03%) (46.74%) (38.32%) (49.13%) (52.37%) (85.64%) (27.99%) —
ROIC
0.00% 0.00% (1,041.19%) 0.00% 0.00% 0.00% 0.00% —
Return on Tangible Assets
(135.02%) (62.03%) (66.65%) (72.66%) (29.11%) (232.52%) (14.56%) —
Average Days of Receivables
0.00 0.00 — 0.00 — — — —
Research and Development Expense of Revenue
531.79% 363.85% 0.00% 0.00% 0.00% 0.00% 0.00% —
Selling, General and Administrative Expense of Revenue
160.15% 157.44% 0.00% 0.00% 0.00% 0.00% 0.00% —
Intangible Assets out of Total Assets
0.00 0.02 0.14 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
85.16% 80.17% 0.00% 0.00% 0.00% 0.00% — —
Graham Net Nets
0.48 1.05 — — — — — —
Graham Number
0.00 0.00 — — — — — —
Earnings Yield
(112.17%) (83.33%) — — — — — —
Free Cash Flow Yield
(88.87%) (63.51%) — — — — — —
Revenue per Share
0.22 0.28 0.00 0.00 0.00 0.00 0.00 —
Operating CF per Share
(1.02) (0.99) (1.77) (2.70) (4.16) (9.78) (0.07) —
Capex per Share
0.00 0.00 (0.17) (0.19) (0.06) (1.44) 0.00 —
Free Cash Flow per Share
(1.02) (0.99) (1.94) (2.90) (4.22) (11.22) (0.07) —
Cash per Share
1.10 2.20 3.03 5.47 32.52 7.84 0.57 —
Shareholders Equity per Share
0.86 2.07 3.15 4.87 30.77 (15.17) 0.56 —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Book value per Share
0.86 2.07 3.15 4.87 30.77 (15.17) 0.56 —
Free Cash Flow
(63.51) (57.91) (77.43) (95.73) (35.87) (11.57) (2.24) —
Working Capital
50.97 114.76 98.85 154.98 259.97 4.41 18.97 —
Capital Expenditures
(0.01) (0.24) (6.73) (6.40) (0.54) (1.48) — —
Net Current Asset Value
33.99 96.01 76.58 136.06 259.97 (17.69) 18.96 —
EV/EBIT
0.00 0.42 — — — — — —
Capex to Sales
0.00 0.01 0.00 0.00 0.00 0.00 — —
Net Profit Margin
(574.55%) (478.95%) 0.00% 0.00% 0.00% 0.00% 0.00% —
Price to Operating Income
0.00 0.00 — — — — — —
Other line items
Depreciation/Fixed assets
0.19 (0.32) (0.24) 0.06 0.64 0.43 0.00 —
Cash ROIC
(58.73%) (27.12%) (33.50%) (29.42%) (6.76%) 147.88% (5.97%) —
Accounts Receivable Turnover
0.00 0.00 — — — — — —
Accounts Payable Turnover
0.30 0.11 0.00 0.19 0.19 0.57 0.00 —
Inventory Turnover
0.00 0.00 — 0.00 0.00 0.00 — —
Average Days of Payables
1,663.75 3,733.76 0.00 1,410.90 3,486.90 885.37 0.00 —
Days of Inventory on Hand
0.00 0.00 — 0.00 0.00 0.00 — —
Average Payables
7.87 4.38 5.50 9.52 6.51 0.78 0.78 —
Average Assets
124.35 165.45 192.55 245.70 145.09 14.98 9.90 —
Average Common Equity
87.08 123.23 143.26 211.07 122.83 (9.26) (9.26) —

Fold the line items

Columns are period end dates